Dark

AGEN
Agenus Inc.
stock NASDAQ

At Close

Apr 23, 2026 3:59:57 PM EDT

3.77USD-4.315%(-0.17)839,655

3.75Bid 3.77Ask 0.02Spread

Pre-market

Apr 22, 2026 9:08:30 AM EDT

3.99USD+1.330%(+0.05)0

After-hours

Apr 23, 2026 4:42:30 PM EDT

3.81USD+1.061%(+0.04)1,000

OverviewOptionsHistoricalExchangesShortsNews

Jan 5, 2022

08:30AM EST Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that management will participate in the following upcoming investor conferences: GlobeNewswire Inc

Dec 22, 2021

08:36AM EST Agenus Reports Balstilimab Plus Zalifrelimab Data Published In 'Journal Of Clinical Oncology': 'Objective response rate (ORR) of 32.8%' Benzinga

08:30AM EST -- Objective response rate (ORR) of 32.8% in PD-L1-positive patients and 25.6% in all patients regardless of PD-L1 status -- Both ORRs and durability of responses are higher than what has been demonstrated with approved therapies for these patients -- Median duration of response (mDoR) not yet reached after 21 months median follow-up GlobeNewswire Inc

Dec 16, 2021

10:14AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2021 Benzinga

06:19AM EST HC Wainwright & Co. Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $12 Benzinga

Nov 17, 2021

08:30AM EST Agenus to Participate in 4th Annual Evercore ISI HealthCONx Conference GlobeNewswire Inc

Nov 12, 2021

07:00AM EST Clinical Activity of AGEN1181 Demonstrated Across Nine GlobeNewswire Inc

Nov 9, 2021

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

11:41AM EST Agenus Q3 EPS $0.72 Beats $0.46 Estimate, Sales $252.95M Beat $183.11M Estimate Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

08:01AM EST Agenus to Participate in Fireside Chat at the B. Riley Fall 2021 GlobeNewswire Inc

08:00AM EST Agenus Corporate Update and Third Quarter 2021 Financial Report GlobeNewswire Inc

Nov 4, 2021

08:30AM EDT Agenus to Participate in Webcast Hosted by William Blair to GlobeNewswire Inc

Oct 25, 2021

08:30AM EDT Agenus to Provide Corporate Update and Third Quarter 2021 GlobeNewswire Inc

Oct 22, 2021

08:05AM EDT UPDATE: Agenus Will Launch Accelerated Development Of Balstilimab In Combo With AGEN1181 For Multiple Tumor Types Benzinga

08:04AM EDT UPDATE: Agenus To Discontinue Its Ongoing Confirmatory Trial In Certain Balstilimab Population, Will Save Co. $100M+ In R&D Expenses Benzinga

08:03AM EDT Agenus Reports Voluntary Withdrawal Of Its Biologics License Application At FDA's Recommendation Following Full Approval Of Pembrolizumab Benzinga

08:00AM EDT Agenus Provides Update on Balstilimab Development GlobeNewswire Inc

Oct 12, 2021

08:38AM EDT Agenus Reports Will Receive $20M Milestone Payment From Bristol Myers Related To Dosing Of First Patient For TIGIT Bispecific Antibody Benzinga

08:34AM EDT Agenus To Receive $20 Mln Milestone Payment From Bristol Myers Squibb With Dosing Of First Patient For AGEN1777 RTTNews

08:30AM EDT Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb GlobeNewswire Inc

Oct 1, 2021

08:07AM EDT Agenus To Present AGEN1181 Clinical Data At SITC On Nov. 10-14 Benzinga

08:00AM EDT Agenus to Present AGEN1181 Clinical Data at SITC GlobeNewswire Inc

Sep 17, 2021

07:36AM EDT The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold Benzinga

Sep 16, 2021

06:25PM EDT -- Objective response rate of 33% and median duration of response not reached with 19.4 months median follow-up in PD-L1+ tumors; expands benefit of anti-PD-1 alone -- Improved responses seen across all histology subgroups including populations of patients unresponsive to other therapies -- Dr. David OMalley to present data in an oral presentation on Sept. 19th GlobeNewswire Inc

Sep 10, 2021

07:33AM EDT Agenus Subsidiary, SaponiQx Announces Collaboration With Soaring Eagle Acquisition Corp. SPAC Merger Partner Ginkgo Bioworks Benzinga

07:30AM EDT New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant GlobeNewswire Inc

Sep 9, 2021

08:00AM EDT Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell, PhD, President and COO of Agenus, will participate in the following upcoming conferences: GlobeNewswire Inc

Sep 2, 2021

10:10AM EDT Agenus Sponsored Study Titled 'A Phase 2 Study of Balstilimab Independently or in Combination With Zalifrelimab in Cervical Cancer' Posted To ClinicalTrials.gov; Study Is Not Recruiting Benzinga

Aug 31, 2021

08:15AM EDT The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical Benzinga

Aug 27, 2021

07:35AM EDT The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration Benzinga

Aug 26, 2021

09:00AM EDT -- Objective response rate of 20% and median duration of response not reached with 14.6 month median follow-up in PD-L1+ tumors -- Responses seen across all histology subgroups including populations of patients unresponsive to other therapies GlobeNewswire Inc

Aug 25, 2021

07:30AM EDT The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug Benzinga

Aug 24, 2021

10:52AM EDT Agenus Granted U.S. Patent Titled 'Anti-CD137 antibodies and methods of use thereof' Benzinga

08:09AM EDT The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal Benzinga

Aug 13, 2021

03:35PM EDT Finally! An ETF for Bargain-Hunting Investors Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

08:05AM EDT Recap: Agenus Q2 Earnings Benzinga

07:48AM EDT Agenus Q2 EPS $(0.37) Misses $(0.24) Estimate, Sales $10.73M Miss $20.41M Estimate Benzinga

07:45AM EDT -- $200M received from BMS for anti-TIGIT bispecific antibody collaboration -- FDA cleared IND for AGEN1777 clinical enrollment -- AGEN1181 rapidly advancing in the clinic; data to be presented in 2H 2021 -- Cell therapy subsidiary MiNK Therapeutics filed confidential S-1 for planned IPO -- FDA accepted balstilimab BLA for Priority Review with December PDUFA date GlobeNewswire Inc

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 2, 2021

04:05PM EDT Agenus to Participate in the BTIG Virtual Biotechnology Conference GlobeNewswire Inc

Jul 28, 2021

08:33AM EDT Agenus Subsidiary MiNK Therapeutics Announces Confidential Submission Of Draft Registration Statement For Proposed IPO Benzinga

08:30AM EDT MiNK Therapeutics Announces Confidential Submission of Draft GlobeNewswire Inc

Jul 26, 2021

04:05PM EDT Agenus to Provide Corporate Update and Second Quarter 2021 GlobeNewswire Inc

Jul 7, 2021

04:05PM EDT Agenus to Participate in Resistance-Focused Oncology Panel at the GlobeNewswire Inc

Jul 6, 2021

08:32AM EDT Agenus Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777 Benzinga

08:30AM EDT Agenus Closes $200M Upfront BMS Collaboration and Announces FDA GlobeNewswire Inc

Jun 29, 2021

12:48PM EDT Agenus Publishes Clinical Trial Titled 'Balstilimab in Patients With Recurrent Cervical Cancer.' To ClinicalTrials.Gov Site Benzinga

Jun 21, 2021

09:00AM EDT Agenus to Participate in the Raymond James 2021 Human Health GlobeNewswire Inc

Jun 17, 2021

10:23AM EDT Agenus Gains As Balstilimab US Application Accepted For Review In Cervical Cancer Benzinga

08:37AM EDT FDA Accepts Agenus' BLA For Balstilimab For The Treatment Of Recurrent Or Metastatic Cervical Cancer RTTNews

08:33AM EDT Agenus Announces U.S. FDA Acceptance And Priority Review Of Balstilimab Biologics License Application For Treatment Of Recurrent Or Metastatic Cervical Cancer Benzinga

08:30AM EDT Agenus Announces U.S. FDA Acceptance and Priority Review of GlobeNewswire Inc

Jun 15, 2021

08:30AM EDT Agenus Announces Virtual Annual Shareholders Meeting GlobeNewswire Inc

Jun 4, 2021

09:15AM EDT Agenus Says Co's Presentations At ASCO 2021 'Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373' Benzinga

09:09AM EDT Agenus Presentations at ASCO 2021 Demonstrate GlobeNewswire Inc

Jun 1, 2021

04:05PM EDT Agenus to Participate in Fireside Chat at the Jefferies 2021 GlobeNewswire Inc

10:02AM EDT Agenus Granted U.S. Patent Titled 'Anti-TIGIT antibodies and methods of use thereof' Benzinga

May 20, 2021

07:10AM EDT Agenus Presents New Data on Balstilimab and AGEN2373 in ASCO Abstracts Benzinga

May 18, 2021

02:38PM EDT Mid-Afternoon Market Update: Nasdaq Turns Negative; Ultralife Shares Spike Higher Benzinga

12:18PM EDT Mid-Day Market Update: TOMI Environmental Solutions Falls After Q1 Results; Agenus Shares Jump Benzinga

11:00AM EDT Shares of Agenus Inc. (AGEN) are surging more than 25% Tuesday morning after the company granted exclusive global license to Bristol-Myers Squibb Company (BMY) for Agenus' anti-TIGIT bispecific antibody Program, AGEN1777. RTTNews

10:27AM EDT Mid-Morning Market Update: Markets Mixed; Walmart Tops Q1 Expectations Benzinga

09:16AM EDT Bristol Myers Inks $1.6B Licensing Agreement For Agenus' Bispecific Antibody Program In Solid Tumors Benzinga

08:13AM EDT Clinical-stage immuno-oncology company Agenus Inc. (NASDAQ: AGEN) announced an agreement under which Bristol-Myers Squibb Co. (BMY) will be granted a global exclusive license to its proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target. RTTNews

07:35AM EDT Bristol-Myers Squibb, Agenus Enter Global License For Anti-TIGIT Bispecific Antibody Program RTTNews

07:34AM EDT Agenus And Bristol Myers Squibb Announce Exclusive Global License For Agenus' Anti-TIGIT Bispecific Antibody Program; Agenus To Receive Upfront Payment Of $200M And Up To $1.36B In Milestones Benzinga

07:31AM EDT Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Agenus executives will conduct a conference call to discuss the global licensing agreement between Agenus and Bristol Myers Squibb at 8:30 a.m. ET today. GlobeNewswire Inc

07:30AM EDT Agenus and Bristol Myers Squibb Announce Exclusive Global License GlobeNewswire Inc

May 6, 2021

08:09AM EDT Agenus Q1 EPS $(0.27) Beats $(0.31) Estimate, Sales $12.00M Miss $14.53M Estimate Benzinga

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

07:45AM EDT -- Balstilimab BLA submitted to FDA for recurrent/metastatic cervical cancer -- Balstilimab and AGEN2373 data to be presented at ASCO -- iNKT cell therapy Phase 1 initiated in cancer GlobeNewswire Inc

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

May 5, 2021

01:04PM EDT Agenus Shares Move Higher; Co Granted Australian Patent Titled 'VACCINES FOR TREATMENT AND PREVENTION OF CANCER' Benzinga

Apr 22, 2021

04:05PM EDT Agenus to Provide Corporate Update and First Quarter 2021 GlobeNewswire Inc

Apr 19, 2021

08:32AM EDT Agenus Says Submits Balstilimab Biologics License Application To The U.S. FDA For Patients With Recurrent Or Metastatic Cervical Cancer Benzinga

08:30AM EDT -- Submission has been made for review under the accelerated approval pathway GlobeNewswire Inc

Apr 14, 2021

08:41AM EDT Agenus Doses First Cancer Patient With AgenT-797 INKT Cell Therapy RTTNews

08:32AM EDT Agenus Doses First Cancer Patient With iNKT Cell Therapy Benzinga

Apr 10, 2021

08:35AM EDT -- 7 objective responses observed to date in multiple tumor types -- New responses reported in patients with melanoma and ovarian cancer -- Benefit seen in patients typically unresponsive to I-O agents GlobeNewswire Inc

Apr 6, 2021

08:30AM EDT Agenus to Participate in Webcast Hosted by William Blair on GlobeNewswire Inc

Mar 15, 2021

08:25AM EDT Agenus: Q4 Earnings Insights Benzinga

07:46AM EDT Agenus Q4 EPS $(0.20) Beats $(0.22) Estimate Benzinga

07:45AM EDT -- Completion of balstilimab BLA filing on target for 1H 2021 -- New clinical data for AGEN1181 to be presented at AACR -- TIGIT bispecific AGEN1777 IND to be filed in 2Q 2021 -- iNKT cell therapy cancer trials to commence in 1H 2021 GlobeNewswire Inc

04:53AM EDT Earnings Scheduled For March 15, 2021 Benzinga

Mar 14, 2021

08:14AM EDT Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations Benzinga

Mar 10, 2021

04:34PM EST Agenus To Present New Clinical Data On Its AGEN1181 At The AACR 2021 Benzinga

04:33PM EST -- Clinical benefit in previously unresponsive tumors, including CRC, ovarian, and endometrial -- Confirmed responses in cold tumors as characterized by MSS -- No neuroendocrine toxicities or hypophysitis -- Registrational trials planned to commence in 2021 GlobeNewswire Inc

Mar 2, 2021

08:30AM EST Agenus to Provide Corporate Update and Fourth Quarter & Full Year GlobeNewswire Inc

Feb 10, 2021

10:36AM EST Agenus 13G Filing From Vanguard Shows Raised Stake From ~8.5M Shares To ~9.5M Shares, Or 5.01% Stake In Co. Benzinga

Feb 9, 2021

05:07PM EST Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the appointment of Andy Hurley as its Chief Commercial Officer. GlobeNewswire Inc

11:00AM EST -- Season 1 Episode 1 (S1E1) on Optimally Targeting TIGIT GlobeNewswire Inc

08:47AM EST Agenus Announces Addl Confirmed Objective Clinical Responses From Phase 1/2 Trial Of AGEN1181 RTTNews

08:46AM EST Agenus Reports 6 Total Confirmed Objective Clinical Responses In Colon, Ovarian, Endometrial Cancers, No Complement-Mediated Toxicities Reported Benzinga

08:45AM EST -- 6 total confirmed objective clinical responses in colon, ovarian, and endometrial cancers -- No complement-mediated toxicities reported GlobeNewswire Inc

Feb 5, 2021

07:44AM EST The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street Benzinga

Feb 4, 2021

04:01PM EST Jon Najarian Sees Unusual Option Activity In JetBlue Airways, Agenus Benzinga

10:47AM EST Encouraging Interim Data From Early-Stage COVID-19 Study With Cell Therapy Lifts Agenus Shares Benzinga

08:30AM EST -- 3 out of 4 intubated patients were discharged after treatment -- 2 out of 4 patients were extubated within 24 hours of dosing GlobeNewswire Inc

Jan 26, 2021

08:40AM EST Agenus Says Enters Into Collaboration With Nelum For Zalifrelimab Combination Benzinga

08:30AM EST Agenus Enters into Clinical Collaboration with Nelum for GlobeNewswire Inc

Jan 19, 2021

12:09PM EST Agenus to Participate in B. Riley Securities' Oncology Investor GlobeNewswire Inc

Dec 3, 2020

07:45AM EST Completion of Balstilimab BLA Filing Extended To 1H2021 GlobeNewswire Inc

Dec 1, 2020

08:12AM EST Agenus Reports Launch Of Phase 2 Trial Expansion In Colon Cancer For AGEN1181 In Combo With Balstilimab Benzinga

08:00AM EST Agenus Launches Phase 2 Trial Expansion in Colon Cancer for GlobeNewswire Inc

Nov 25, 2020

01:28PM EST Agenus to Participate in Evercore ISI 3rd Annual HealthCONx Conference GlobeNewswire Inc

Nov 19, 2020

08:08AM EST VBI Vaccines Announces Positive Interim Phase 2a Data From VBI-1901 In Recurrent GBM Benzinga

Nov 16, 2020

07:04PM EST Agenus to Participate in Fireside Chat at the Jefferies 2020 GlobeNewswire Inc

Nov 13, 2020

02:43PM EST Agenus and Dr. Steven ODay to Participate in GlobeNewswire Inc

Nov 11, 2020

07:38AM EST The Daily Biotech Pulse: Five Prime Skyrockets, Multiple Conference Presentations On Tap Benzinga

07:30AM EST XOMA Earns First Milestone Payment from 2018 Royalty Purchase GlobeNewswire Inc

Nov 10, 2020

08:49AM EST Agenus Says ILT4 Antibody MK-4830 Enters Phase 2 Benzinga

08:45AM EST -- $10M milestone payment from Merck triggered -- Agenus is eligible for up to an additional $85 million in milestones plus royalties on sales GlobeNewswire Inc

Nov 9, 2020

08:30AM EST Agenus Presents Additional Clinical Responses, Novel Biomarker Data At SITC2020 Benzinga

08:15AM EST Agenus Presents Additional Clinical Responses and Novel Biomarker GlobeNewswire Inc

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 5, 2020

08:15AM EST Agenus Appoints Dr. Steven O'Day Chief Medical Officer Benzinga

Nov 2, 2020

08:46AM EST Agenus Doses First COVID-19 Patient With iNKT Cell Therapy Benzinga

08:45AM EST -- Allogeneic (off the shelf) iNKT cell therapy targets patients with moderate to severe COVID-19 -- iNKT cells designed to clear SARS-CoV-2 virus while reducing harmful inflammation GlobeNewswire Inc

Oct 29, 2020

03:45PM EDT Agenus shares are trading lower after the company reported worse-than-expected Q3 EPS results. Benzinga

07:55AM EDT Agenus Q3 EPS $(0.28) Misses $(0.26) Estimate, Sales $14.83M Beat $14.00M Estimate Benzinga

07:45AM EDT -- Balstilimab rolling BLA filing and FDA review underway -- COVID-19 trial open with patients in screening for iNKT Cell Therapy -- New data and clinical responses with AGEN1181 to be presented at SITC on NOV11 GlobeNewswire Inc

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

04:08AM EDT Earnings Scheduled For October 29, 2020 Benzinga

Oct 20, 2020

10:34AM EDT Agenus to Report Third Quarter Earnings GlobeNewswire Inc

Oct 14, 2020

05:00PM EDT Agenus to Present on Seven Novel Programs at SITC 2020 GlobeNewswire Inc

Oct 13, 2020

08:46AM EDT Agenus Adds Susan Hirsch To Board RTTNews

08:30AM EDT Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the election of Ms. Susan Hirsch to Agenus' Board of Directors. GlobeNewswire Inc

Sep 18, 2020

10:45AM EDT Agenus shares are trading higher after the company presented its results from two large cervical cancer trials at the ESMO. Benzinga

10:13AM EDT Looking Into Agenus's Return On Capital Employed Benzinga

08:37AM EDT Agenus Begins Rolling Submission Of BLA To FDA For Balstilimab RTTNews

08:30AM EDT Agenus Initiates Rolling BLA Submission of Balstilimab for GlobeNewswire Inc

08:30AM EDT Agenus Reports Initiation Of Rolling Biologics License Application Submission For Recurrent/Metastatic Cervical Cancer Benzinga

05:52AM EDT Agenus Presented Results from Two Large Cervical Cancer Trials at ESMO Benzinga

03:00AM EDT -- 160 patient balstilimab (PD-1) monotherapy trial achieves response rates of 14% in all treated patients and 19% in PD-L1 positive patients -- 155 patient balstilimab (PD-1) + zalifrelimab (CTLA-4) combination trial achieves response rates of 22% in all patients and 27% in PD-L1 positive patients GlobeNewswire Inc

Sep 17, 2020

05:06PM EDT Dr. Jennifer Buell Speaks Live at Scientific American Inaugural GlobeNewswire Inc

01:39PM EDT Agenus to Participate in Webcast Hosted by William Blair on GlobeNewswire Inc

Sep 11, 2020

10:29AM EDT Return On Capital Employed Overview: Agenus Benzinga

Aug 31, 2020

08:01AM EDT Paul Clark Joins Agenus Board of Directors PR Newswire

Aug 26, 2020

02:49PM EDT Agenus Announces ESMO Oral Presentation Of Two Clinical Trials Of Balstilimab Alone And In Combination With Zalifrelimab In Recurrent Or Metastatic Cervical Cancer Benzinga

02:47PM EDT Alone and in Combination with Zalifrelimab in Recurrent or Metastatic Cervical Cancer PR Newswire

Aug 6, 2020

10:31AM EDT Agenus Earlier Reported Q2 EPS $(0.28) Misses $(0.27) Estimate, Sales $26.95M Beat $9.33M Estimate Benzinga

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

07:45AM EDT Agenus Q2 Net Loss $48.2 Mln Or $0.28/shr Vs. Net Loss $51.9 Mln Or $0.38/shr Last Year RTTNews

07:31AM EDT Agenus Provides R&D Update & Second Quarter Financial Report PR Newswire

07:19AM EDT Biocryst Pharmaceuticals Q2 EPS $(0.24) Beats $(0.25) Estimate Benzinga

Aug 4, 2020

08:31AM EDT Agenus to Present on Targeting Myeloid Cells in Tumor Microenvironment at the PR Newswire

Jul 29, 2020

02:00PM EDT Agenus R&D update & Second Quarter Earnings Report PR Newswire

Jul 28, 2020

11:29AM EDT Agenus Shares Move To Session High On Volume Following Co. Press Release Co. Received $35M In Immuno-Oncology Deal With Betta Pharma, Co. Eligible To Receive Up To $100M In Potential Milestones Benzinga

11:24AM EDT Agenus Receives $35M In Immuno-Oncology Transaction with Betta Pharmaceuticals PR Newswire

Jul 22, 2020

12:49PM EDT Agenus Files For Potential Mixed Shelf Offering; Size Not Disclosed; Co. Says In Addition, Primary Offering Of Up To $100M Benzinga

Jul 21, 2020

01:33PM EDT Agenus To Participate In A Panel On Cell Therapy For Infectious Diseases At The B. Riley Virtual Infectious Disease Summit Benzinga

01:32PM EDT Agenus To Participate in a Panel on Cell Therapy for Infectious Diseases at the PR Newswire

document.getElementById("FX4174").onerror = function(){this.style.display='none';}; .dark-mode .ddzbNS{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .ddzbNS{ color: #333333; background-color: white; border: 2px solid #333333; }AGENAgenus Inc.stock NASDAQ

AGEN
Agenus Inc.
stock NASDAQ